Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: December 13, 2007
Last updated: November 30, 2010
Last verified: November 2010
This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.

Condition Intervention
Drug: Symbicort

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate & describe asthma control in adult patients w/moderate to severe asthma treated w/Symbicort SMART following the frequency, type & severity of symptoms through the Asthma Control Questionnaire.

Secondary Outcome Measures:
  • to evaluate the safety of Symbicort SMART treatment through the number and type of reported adverse events 2. assessment of patient's satisfaction with the treatment 3.assessment of physician's satisfaction with the treatment

Enrollment: 330
Study Start Date: November 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
pulmonology clinics

Inclusion Criteria:

  • Patients with moderate and severe asthma on Symbicort SMART treatment

Exclusion Criteria:

  • Under 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00573222

Research Site
Cakovec, Croatia
Research Site
Dubrovnik, Croatia
Research Site
Osijek, Croatia
Research Site
Pozega, Croatia
Research Site
Pula, Croatia
Research Site
Rijeka, Croatia
Research Site
Senj, Croatia
Research Site
Sibenik, Croatia
Research Site
Slavonskibrod, Croatia
Research Site
Vinkovci, Croatia
Research Site
Vukovar, Croatia
Zadar, Croatia
Research Site
Zagreb, Croatia
Sponsors and Collaborators
Study Director: Anan Marija Gjurovic AstraZeneca
  More Information

No publications provided Identifier: NCT00573222     History of Changes
Other Study ID Numbers: NIS-RHR-SYM-2007/1
Study First Received: December 13, 2007
Last Updated: November 30, 2010
Health Authority: Not Required:

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Anti-Asthmatic Agents
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses processed this record on November 30, 2015